Skip to main content

Table 5 COPD outcomes according to main morbidities

From: Adherence to inhalers and comorbidities in COPD patients. A cross-sectional primary care study from Greece

 

At least 2 comorbidities

Overweight-Obese

Hypertension

Type II Diabetes Mellitus

Dyslipidaemia

Heart Diseases

COPD outcome

present

absent

p-value

present

absent

p-value

present

absent

p-value

present

absent

p-value

present

absent

p-value

present

absent

p-value

At least 2 exacerbations in the last 12 months

58 (38)

19 (37)

0.999

61 (36)

16 (49)

0.239

63 (42)

14 (25)

0.037

11 (58)

66 (35)

0.081

13 (29)

64 (40)

0.259

12 (48)

65 (36)

0.332

CAT ≥ 10

13 (7)

8 (15)

0.095

19 (10)

3 (8)

0.776

164 (92)

58 (88)

0.436

26 (96)

197 (91)

0.484

57 (93)

166 (90)

0.613

30 (97)

193 (90)

0.326

mMRC ≥ 2

113 (61)

34 (61)

0.999

127 (64)

21 (48)

0.077

113 (61)

39 (57)

0.660

21 (75)

132 (59)

0.151

31 (50)

122 (64)

0.073

24 (75)

128 (58)

0.109

GOLD 2019-C&D status

CAT-based

60 (40)

18 (37)

0.739

64 (38)

14 (45)

0.548

64 (43)

14 (26)

0.023

13 (62)

65 (36)

0.031

15 (33)

63 (40)

0.395

13 (52)

65 (36)

0.186

GOLD 2019-C&D status

mMRC-based

60 (40)

19 (37)

0.869

63 (37)

16 (49)

0.245

65 (43)

14 (26)

0.024

13 (62)

66 (36)

0.031

15 (33)

63 (40)

0.395

13 (50)

66 (37)

0.200

  1. Cell values are presented as n (% of COPD outcome within morbidity status) of subjects with COPD outcome in each comorbid condition group and P-values are given by Chi-square test. Bold faceted text indicates P-values< 0.05. COPD Chronic obstructive pulmonary disease, GOLD 2019 Global Initiative for Obstructive Lung Disease 2019 Guidelines, CAT Chronic Obstructive Pulmonary Disease Assessment Test, mMRC Modified Medical Research Council Dyspnoea Scale